Pace picking up for pharmacologic development in glaucoma therapy

Pace picking up for pharmacologic development in glaucoma therapy

ABSEE PHARMA This German company is pursuing what could become the first neuroprotective agent against glaucoma and dry age-related macular degeneration (AMD). Lead compound AR-13324 lowers IOP by inhibiting ROCK to enhance outflow through the trabecular meshwork and inhibiting aqueous production by...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology Times 2014-09, Vol.39 (17), p.39
1. Verfasser: Gebhart, Fred
Format: Artikel
Sprache:eng
Schlagworte:
Alzheimer's disease
Chief executive officers
Clinical trials
Drug dosages
Glaucoma
Macular degeneration
Ophthalmology
Pharmaceutical industry
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSEE PHARMA This German company is pursuing what could become the first neuroprotective agent against glaucoma and dry age-related macular degeneration (AMD). Lead compound AR-13324 lowers IOP by inhibiting ROCK to enhance outflow through the trabecular meshwork and inhibiting aqueous production by inhibiting NET.
ISSN:0193-032X
2150-7333